Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in Post-Traumatic Stress
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Doxazosin (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 19 Oct 2022 Planned End Date changed from 1 Jun 2021 to 1 Jun 2023.
- 19 Oct 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2023.
- 17 Apr 2018 Status changed from not yet recruiting to recruiting.